Elevated levels of various inflammatory markers are sensitive (but not specific) to BD including C-reactive protein, erythrocyte sedimentation rate, peripheral leukocyte and platelet counts and serum cytokines (TNF-α, IFN-γ, IL-1β, IL-6, and IL-8) [35, 43].
These molecular changes also occurred before overt clinical manifestations, suggesting that the markers are sensitive to more subtle loss of motor neurons.
The use of the 8 markers as a CIMP diagnostic panel has previously been validated, and all of the 8 markers are sensitive and specific markers for CIMP-high [ 36].
Like in previous studies (Kolodner et al, 1999; Verma et al, 1999; Parc et al, 2000) our study shows that mononucleotide markers but not dinucleotide markers are sensitive to show instability in tumours of MSH6 mutation carriers.
Diets can have an impact on postprandial glucose concentrations also in the non-diabetic population; however, it is unclear whether current markers are sensitive to (smaller dietary) changes in glycaemic exposure.
Because biochemical markers are sensitive and dynamic indicators of tissue turnover, they have the potential to provide information on treatment efficacy more rapidly than a variety of imaging methods [ 16].
In an exploratory study investigating the effects of three intra-articular injections of hyaluronic acid (Hylan GF-20) on the evolution of 10 biochemical markers, we have demonstrated that uCTXII, sColl2-1 and sColl2-1NO2 levels were significantly affected by treatment suggesting that these markers are sensitive to metabolic change occurring in one single joint.
While tumour heterogeneity also explains individual variations in treatment response, a monitoring approach based only on a single marker is sensitive to variations in expression of that marker.
This marker is sensitive to the oxygen variations: it is metabolized at pO2 lower than 10 mmHg, only in viable cells (Durand and Raleigh, 1998; Evans et al, 2000).
